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Abstract Calpastatin molecule contains four repeated inhibition 
domains, each having highly conserved internal regions A, B and 
C. The synthetic oligopeptides of regions A and C had no calpain 
inhibition activity while region B oligopeptide showed weak inhi- 
bition activity. Real-time biomolecular interaction analysis using 
a BIAcore instrument revealed that the bacterially expressed 
calmodulin-like domain of the calpain large subunit (L-CaMLD) 
and that of the small subunit (S-CaMLD) interacted, in a Ca 2÷- 
dependent fashion, preferentially with the immobilized synthetic 
oligopeptide of region A and that of region C, respectively. Calm- 
odulin showed no specific binding to these oligopeptides. The 
tripartite structure of the calpastatin functional domain may con- 
fer the specific interactions with the protease domain and the two 
CaMLDs of calpain. 
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1. Introduction 
Both calpain (EC 3.4.22.17, Ca2+-dependent cysteine pro- 
tease) and its endogenous inhibitor protein calpastatin are 
known to be widely distributed in animal cells (see [1-4] for a 
review). A calpastatin molecule contains four internally re- 
peated omains (140 amino acid residues, domains 1-4) and a 
unique domain on its N-terminal side (domain L) [5,6]. Calpain 
inhibitory activity has been detected in each repeated omain 
but not for domain L [7]. Conserved residues among the four 
repeated omains are not randomly distributed but are clus- 
tered in three restricted regions designated as A, B and C, 
respectively, within each domain. Structure-function a alyses 
of recombinant calpastatins with various deletions in their in- 
hibitory domains revealed that region B was essential for inhi- 
bition [8-10], Moreover, synthetic oligopeptides of 16-34 resi- 
dues containing region B of domain 1 retained inhibition activ- 
ity, though with less than one-tenth of the inhibition activity of 
the whole domain [9-11]. The kinetic analyses using calpastatin 
fragments containing region B have revealed that calpastatin 
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inhibits calpain by virtue of competition with substrates [8,9]. 
Although regions A and C were suggested to play roles in 
potentiating the inhibition activity, the mechanism remains un- 
known. 
/l-Calpain (low CaZ+-requiring form, calpain I) and m-cal- 
pain (high Ca2+-requiring form, calpain II) are heterodimers of
a small subunit (30 kDa) and a large subunit (80 kDa) [1-4]. 
The large subunit has four structurally distinct domains, in- 
cluding a catalytic domain with a high degree of sequence 
homology with cysteine proteases and a calmodulin-like do- 
main (CaMLD) [12]. The small subunit is a regulatory protein 
which contains a sequence similar to the CaMLD of the large 
subunit [13]. Physical association of calpain and calpastatin 
occurs only in the presence of Ca 2+ [14,15]. The role of Ca 2+ in 
the complex formation might be explained by requirement of 
the ion to induce conformational change of calpain into a form 
that is able to bind to the inhibitor near the catalytic enter. 
Surprisingly, however, Nishimura and Goll reported that the 
fragments containing CaMLDs generated on calpain autolysis 
bound to a calpastatin-immobilized column in the presence of 
Ca 2÷ and were eluted with a chelating reagent [16]. The mecha- 
nism of the CaZ+-dependent i eraction between calpain and 
calpastatin, however, has not yet been clarified. Here we show 
that the CaMLD of the large subunit (L-CaMLD) and that of 
the small subunit (S-CaMLD) expressed in E. coli bind prefer- 
entially to oligopeptides of regions A and C, respectively, in a 
CaZ+-dependent fashion. 
2. Materials and methods 
2.1. Materials 
Human/t-calpain was purified from erythrocytes a described previ- 
ously [17]. Recombinant human calpastatin domain 1 (hCSD 1, residues 
137-277) and L-CaMLD of/.t-calpain were prepared and purified as 
described [18]. Synthetic oligopeptides were custom-ordered from 
Sawaday Technology Inc., Takara Shuzo, or synthesized as described 
previously [18,19]. Oligopeptides used in the present study are: DIAl9 
(SGKSGMDAALDDLIDTLGG); D1C19 (SKPIGPDDAIDALS- 
SDFTS); D 1B27cys25(CSSTYIEELGKREVTIPPKYRELLAKK) 
and CNApep25 (CARKEIIRNKIRAIGKMARVFSVLR). Sensor 
chips CM5, amine- and thiol-coupling kits, and Tween 20 for BIAcore 
were obtained from Pharmacia Biosensor AB (Uppsala, Sweden). CaM 
purified from bovine brain was obtained from Sigma Chemical Co. (St. 
Louis, USA). 
2.2. Assay of calpain inhibition 
Digestion of casein, 2 mg/ml, was performed using 8 pg/a-calpain i  
a reaction volume of 50 pl in 20 mM Tris-HCl, pH 7.5, 50 mM NaCI, 
0.5 mM Ca 2+, 5 mM 2-mercaptoethanol, in the presence or absence of 
calpastatin peptides, at 25°C for 30 min. Reactions were terminated by 
adding SDS-containing sample loading buffer for SDS-PAGE, and 
boiled for 2 min. SDS-PAGE was performed on 15% slab gels, followed 
by staining with Coomassie brilliant blue R250. 
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Fig. 1. The inhibition potency of calpastatin domain 1 and oligopeptides of regions A, B and C. (Top panel) Repeat domain structure of human 
calpastatin. Regions A, B and C, which are highly conserved among the four internally repeated omains 1-4 are marked. (Middle panel) Casein 
was digested with/t-calpain with or without calpastatin domain 1 peptides as described in section 2. The mixture containing no Ca 2. was processed 
as a control (lane 1). After SDS-PAGE using a 15% slab gel, the gel was stained with Coomassie brilliant blue R250 (CBB-staining). Lane 1, control; 
lane 2, without calpastatin peptide; lane 3, 1/tM hCSD1; lane 4, I / IM DlB27cys ; lane 5, 1 tiM D1A19; lane 6, 1/tM D1C19; lane 7, 1/~M each 
DI B27cys, D1A19 and DICI9; lane 8, 1/~M each D1A19 and D1CI9; lane M, SDS-PAGE molecular mass standards, Low range (Bio-Rad). (Bottom 
panel) Aliquots of the mixtures hown in the middle panel were analyzed by Western blotting. After SDS-PAGE using a 10% slab gel, samples were 
transferred to a nylon membrane filter (Immobilon-P, Millipore) and detected with anti-L-CaMLD antibody. Prestained SDS-PAGE standards, Low 
range (Bio-Rad), were used for molecular mass calibration (Lane M). Unprocessed (80 kDa) and processed (76 kDa, 55 kDa and 34 kDa) forms 
ofp-calpain are indicated beside the marker lane. 
2.3. Purification of S-CaMLD expressed in E. coli 
The expression plasmid of S-CaMLD (pET-S-CaMLD) was con- 
structed similarly to that of L-CaMLD (pET-p-L-CaMLD) [18,20]. 
Briefly, the cDNA fragment encoding CaMLD of the pig calpain small 
subunit (S-CaMLD) were prepared by the PCR method using the 
previously isolated cDNA clone as a template [13], and inserted into the 
BamHI site of plasmid pET-3d (a vector for expression by T7 RNA 
polymerase; from Novagen, Madison, USA). The S-CaMLD was ex- 
pressed in E. coli strain BL21 (DE3)pLysE as described before [18]. The 
supernatant cell lysate was filtered through a 0.45-pro cellulose acetate 
membrane filter and purified using oligopeptide of D 1C 19 immobilized 
on a NHS-activated HiTrap Sepharose column (Pharmacia). The col- 
umn was equilibrated with buffer B (20 mM Tris HCI, pH 7.5, 0.1 mM 
EDTA, 5 mM 2-mercaptoethanol, and 50 mM NaC1) containing 1% 
Triton X- 100, and 0.5 mM CaClz. The crude S-CaMLD was added with 
Triton X-100, NaCI, CaCl2 to a final concentration f 1%, 50 mM, and 
0.5 mM, respectively, and then applied to the column. The column was 
washed with 10 vols. of buffer B, containing 0.1% Triton X-100, and 
0.5 mM CaC12, further washed with 20 vols. of buffer B, containing 
0.5 mM CaC12. The adsorbed CaMLD was eluted from the column with 
buffer B containing 1mM EGTA. 
2.4. Real-time biomolecular interaction analysis 
Real-time analyses of the Ca2+-dependent i teraction between 
CaMLDs and calpastatin oligopeptides were performed using a 
BIAcore instrument (Pharmacia Biosensor). The principle and applica- 
tion of the system employing surface plasmon resonance (SPR) detec- 
tion was described by Karlsson et al. [21]. Coupling of DIAl9 (calcu- 
lated pI, 4.37) and D 1C 19 (calculated pI, 3.45) to the sensor chips CM5 
were performed by the EDC/NHS method under high salt conditions 
at pH 8.5 as described [18]. Calcineurin oligopeptide (CNApep25) was 
immobilized to a sensor chip CM5 by the ligand thiol method [19]. The 
SPR measurements for the binding of CaMLDs and CaM to oligopep- 
tides were performed at 2/tl/ml in buffer F (20 mM Tris-HCl, pH 7.5, 
150 mM NaCI, 1 mM EGTA, 1.5 mM CaCI2, 0.005% Tween 20). The 
sensor chips were regenerated after each analysis cycle by injecting 
6 ml of buffer F without CaCI2, and then initialized with continuous 
flow of buffer F. 
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3. Results and discussion 
Calpastatin isa specific inhibitor of calpain, and has not been 
known to inhibit any other proteases [1-3]. Absence of signifi- 
cant homology at the primary structure level with any other 
protease inhibitors, including the cystatin superfamily (a class 
of inhibitors of cysteine proteases), may account for this spec- 
ificity [6]. In other words, the inhibition mechanism of calpa- 
statin could not be readily inferred from other protease inhibi- 
tor systems. Fig. 1 (top panel) shows the schematic structure 
of human calpastatin. The highly conserved internal repeat 
regions A, B and C are located on separate xons in the human 
calpastatin gene, suggesting distinct roles in inhibitory function 
[11,22]. Moreover, regions A and C have similar sequences 
[6,20]. Recently we showed that the L-CaMLD of/.t-calpain 
bound in a Ca2+-dependent fashion to calpastatin domain 1 but 
not to the region B oligopeptide, by using a Sepharose column 
immobilizing the L-CaMLD fused with glutathione-S-trans- 
ferase [20]. Furthermore, the oligopeptide of D1AI9 bound 
specifically to the L-CaMLD [18]. The presence of the S- 
CaMLD in the small subunit of calpain, as well as the finding 
of similar motifs between regions A and C, motivated us to 
examine recognition specificity between the CaMLDs. We also 
investigated the roles of regions A, B and C in calpain inhibition 
and discussed the functional significance of the presence of 
these three regions in the calpastatin molecule. 
In agreement with previous reports [9-11], the region B oli- 
gopeptide D1B27cys had calpain inhibition activity with a 
weaker potency than the full-size domain 1 (Fig. 1, middle 
panel, lanes 3 and 4). Although regions A and C are known 
to be important for potentiation of the inhibition activity of 
-7 
Z t~ 
calpastatin [8-10,23], the oligopeptides corresponding to these 
regions howed neither inhibition activity by themselves (lanes 
5, 6 and 8) (even up to 100/IM; data not shown) nor potentiated 
the activity of D1B27cys when mixed together (lane 7). These 
data indicate that the tethered regions of A, B and C are re- 
quired to exert full inhibition activity. 
Several reports have indicated that Ca2+-dependent autolytic 
conversion of/l-calpain from the 80 kDa form to the 76 kDa 
form precedes before it exerts proteolytic activity toward casein 
and other substrates, hence calling the process 'activation' of 
/l-calpain [3,4,24]. In agreement with the above notion, Western 
blot analysis using anti-L-CaMLD antibody, which was raised 
in rabbits using purified L-CaMLD, revealed that the 80 kDa 
form of H-calpain was autolyzed and converted to the 76 kDa 
form during caseinolysis (Fig. 1, bottom panel). Faint bands 
corresponding to 55 kDa and 34 kDa were also detected. The 
recombinant human calpastatin domain 1 (hCSD 1) blocked the 
autolysis (lane 3), but the region B oligopeptide did not 
(lane 4). 
Previously we reported the expression of the recombinant 
L-CaMLD in E. coli and Ca2+-dependent affinity purification 
of the protein using a D1A19-Sepharose column [18]. A similar 
approach was taken to obtain recombinant S-CaMLD from 
E. coli. As illustrated in Fig. 2 (upper panel), the cDNA frag- 
ment containing the region corresponding to amino acid resi- 
dues 84-266 of the small subunit of pig calpain was inserted into 
the BamHI  site of pET-3d and expressed by T7 RNA polym- 
erase. A high level of S-CaMLD expression was observed (Fig. 
2, lower panel, lane 1) and the protein was mostly recovered in 
the soluble fraction (lane 2). When the crude S-CaMLD was 
applied to the DI A 19-Sepharose column in the buffer contain- 
m 
-r-  
E 
n~ 
pET-S-CaMLD "-t l CaMLD 
/ 
MASMTGGQQMGRIHYSNIEA ....... 
I 
84 
266 
M 
97.4~ 
66.0~ 
45.0 
31.0 
21.5 
14.5 
1 2 3 4 5 6  7 8 
Fig. 2. Expression and purification of the recombinant S-CaMLD from/~ coli. (Upper panel) Schematic representation f the expression plasmid 
of S-CaMLD. The cDNA fragment corresponding to the CaMLD of the small subunit (S-CaMLD) was inserted into the BamHl site of pET-3d, 
an expression vector for T7 RNA polymerase. The resultant plasmid was designated pET-S-CaMLD. The N-terminal peptide sequence encoding 
T7 gene 10 is underlined. (Lower panel) SDS-PAGE analysis of the S-CaMLD prepared from E, coli. The S-CaMLD was purified by affinity 
chromatography using an oligopeptide column (D 1C 19). The supernatant of the E. coli lysate was applied to the column in buffer containing Ca 2+ 
and the adsorbed S-CaMLD was eluted with buffer containing EGTA as described in section 2. Samples were analyzed by SDS-PAGE on a 15% 
slab gel. Lanes 1, total ysate; 2, supernatant; 3,flow-through fraction; 4 and 5, wash fractions; 6-8, elution fractions. M, molecular mass SDS-PAGE 
standards, Low range (Bio-Rad). Arrows indicate the S-CaMLD. 
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Fig. 3. BlAcore analysis of the Ca2+-dependent interaction ofCaMLDs 
with DIC19. (Top and middle panels) Representative overlaid sen- 
sorgrams illustrating the real-time binding of S-CaMLD (panel A) at 
12.5, 25, 50, 100 and 200 nM, from bottom to top, and L-CaMLD 
(panel B) at 125,250, 500, 1000 and 2000 nM, from bottom to top, to 
the oligopeptide D1C19 immobilized on the biosensor chip. Analysis 
was performed with buffer F. Arrows indicate phases of (a) association, 
(b) dissociation and (c) regeneration. Regeneration was performed by 
washing the sensor chip with buffer F without Ca 2+. (Bottom panel) 
Scatchard plot analysis. Relative response values expressed as steady- 
state binding (Req) at each protein concentration i  panels A and B were 
estimated by extrapolating dR/dt (time derivative of relative response, 
binding rate) to zero using the kinetics evaluation software installed in 
B1Acore. The reciprocal of the slope gives a value for the dissociation 
constant (KD) from the following equation: Req/C = Rmax/g D--Req/KD. 
Req, steady-state binding value; C, CaMLD concentration; R .... maxi- 
mum binding capacity of the immobilized oligopeptide. S-CaMLD (e); 
L-CaMLD (©). 
ing Ca 2÷, most S-CaMLD was recovered in flow-through frac- 
tions (data not shown). In contrast, most S-CaMLD was ab- 
sorbed to the D1C19 immobilized-Sepharose column and little 
S-CaMLD was observed in the flow-through fraction (lane 3). 
After extensive washing, the adsorbed S-CaMLD was eluted 
from the column with buffer containing 1mM EGTA and no 
Ca 2+ (lanes 6 and 7). 
The Ca2+-dependent binding of S-CaMLD to D1C19 was 
further examined by using a biomolecular interaction analysis 
biosensor instrument, BIAcore. Solutions of the purified S- 
CaMLD were passed over the D1C19-immobilized biosensor 
chip in the presence of Ca 2+. Fig. 3 (top panel) displays an 
example of overlaid sensorgrams u ing five different concentra- 
tions of S-CaLMD (12.5-200 nM). Rates of association (dR/d0 
were analyzed with kinetics evaluation software installed in 
BIAcore. The plots of dR/dt vs. relative response gave linear 
relationships (data not shown), and relative response values 
expressed as steady-state binding (Req) were estimated by ex- 
trapolating dR/dt  to zero. The reciprocal of the slope in a 
Scatchard plot gave a value of the dissociation constant (KD) 
of 3.1 x 10 8 M for S-CaMLD (Fig. 3, bottom panel). The 
binding of L-CaMLD to the D1C19-immobilized sensorchip 
was weak and required higher concentrations of the protein for 
the analysis (125 2000 nM) (Fig. 3, middle panel). Scatchard 
analysis gave a value of KD = 3.5 X 10 _7 M (Fig. 3, bottom 
panel), indicating that D1C has approximately 10 fold higher 
affinity to S-CaMLD than to L-CaMLD. 
The binding specificity of CaMLDs were further clarified by 
using sensorchips immobilizing different oligopeptides. Fig. 4 
displays ensorgrams using 50 nM of L-, S-CaMLD or CaM. 
The L-CaMLD bound preferentially to D1A19 (top panel) 
while S-CaMLD bound to D1C19 (middle panel). Calmodulin 
(CAM) did not show significant binding to these oligopeptides 
while didi show specific binding to a 25-residue oligopeptide 
(CNApep25) of calcineurin (Ca2+/CaM-dependent protein 
phosphatase) (bottom panel) [19]. 
Interaction of CaM and its target Ca2+-dependent binding 
peptides have been well studied (see [25] for a review). A com- 
parison of these CaM-binding sequences reveals little homol- 
ogy in primary structures, but the conspicuous feature common 
to the sequences i the presence of several basic residues and 
no or only a few acidic residues, as in the case of the CaM- 
binding site in calcineurin [19,25]. Furthermore, hydrophobic 
residues frequently repeat in the sequences over a three to four 
residue period. The above feature conforms to a basic am- 
phiphilic c~-helical motif where hydrophobic and basic residues 
are localized on each side of the helical cylinder [25]. Likewise, 
although calpastatin shows little secondary structure in solu- 
tion [10], the potential c~-helix regions found in the conserved 
sequences of regions A and C [8,20] may form amphiphilic 
c~-helical structures upon complexing with the CaMLDs. In- 
deed, the calpastatin domain 1 mutant, which had a substitu- 
tion of one of the conserved hydrophobic Leu residues in region 
A with a helix breaker esidue Pro, demonstrated a striking 
decrease in the binding ability of the L-CaMLD, and also 
showed reduced calpain inhibition activity [23]. 
The unfolded nature of the calpastatin molecule may afford 
the unique physicochemical properties uch as heat and acid 
resistance [1,26], but the inhibitor protein may retain potential 
specific recognition signals toward the CaMLDs. By forming 
acidic amphiphilic ~-helical structures in regions A and C, 
calpastatin may be recognized by the CaMLDs of calpain in the 
presence of Ca 2+. As revealed by the present study, there is a 
preference among the binding sequences among the CaMLDs 
and CaM (Fig. 4). The recognition specificity may reside in the 
difference in the amphiphilic a-helical motifs: acidic or basic 
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Fig. 4. Analysis of binding specificities ofoligopeptides to CaMLDs 
and CaM with BIAcore. The oligopeptides immobilized on the biosen- 
sor chips were: top panel, D1AI9 (region A); middle panel, D1C19 
(region C); bottom panel, CNApep25 (CaM-binding region in human 
calcineurin A-2). Analysis was performed using L-CaMLD, S-CaMLD 
or CaM at 50 nM as described inthe legend tO Fig. 3, and sensorgrams 
were overlaid. Arrows indicate phases of (a) association, (b) dissocia- 
tion and (c) regeneration. 
(CaMLD-binding peptide vs. CaM-binding peptide); conserva- 
tion of particular esidues at certain positions (region A vs. 
region C). 
Binding of Ca 2+ to the two CaMLDs may induce conforma- 
tional change of the enzyme and make the catalytic site (pro- 
tease domain) accessible to substrates and calpastatin. While 
regions A and C bind to the L- and S-CaMLDs, respectively, 
region B occupies the catalytic enter of the protease domain. 
The kinetic analyses using calpastatin fragments containing 
region B have revealed that calpastatin inhibits competition 
with substrates [8,9]. Binding of region B near the catalytic 
center of calpain was further supported by competition experi- 
ments using small molecule inhibitors which reacted with the 
active site cysteine residue [9,15,27]. The tripartite subdomain 
structure of calpastatin (regions A, B and C) may contribute 
to the acquisition of stronger inhibition potency by formation 
of a tighter calpain~alpastatin complex. Verification of the 
proposed model must await the X-ray crystallographic analysis 
of calpain-calpastatin complex. 
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